Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 236

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease

Open access
GEARRY, RICHARD B, BARCLAY, MURRAY L · 2005 · Journal of Gastroenterology and Hepatology

Abstract

The thiopurine drugs azathioprine and 6‐mercaptopurine (6‐MP) are well‐established in the treatment of inflammatory bowel disease (IBD). However, there is a wide inter‐ and intra‐patient variation in the concentrations of active and toxic metabolites due to their complex metabolism and genetic polymorphisms in metabolizing enzymes. Serious drug toxicity leads to cessation of therapy in 9–25% of patients, and there is failure to achieve efficacy in approximately 15% of cases. Advances in the understanding of thiopurine drug metabolism have led to new genetic and metabolite tests to help clinicians optimize thiopurine use. Thiopurine methyltransferase (TPMT) enzyme activity can predict life‐threatening myelotoxicity in the one in 300 patients who are TPMT‐deficient. However, myelotoxicity can also occur in the presence of normal TPMT activity so blood count monitoring should remain standard practice. TPMT testing may also aid in dose individualization. 6‐Thioguanine nucleotides (6‐TGN) are thought to be the predominant active metabolites of the thiopurines. 6‐Thioguanine nucleotide concentration is correlated with bone marrow toxicity and may also correlate with efficacy in IBD. Measurement of 6‐TGN and 6‐methylmercaptopurine (6‐MMP) concentration is most useful in determining why a patient is not responding to a standard dose of a thiopurine drug and may help in avoiding myelosuppression. The ratio of these metabolites can help distinguish non‐compliance, under‐dosing, thiopurine‐resistant and thiopurine‐refractory disease. Some of these investigations are entering routine clinical practice but more research is required to determine their optimal use in patients with IBD. © 2005 Blackwell Publishing Asia Pty Ltd

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1440-1746.2005.03832.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 236

Metadata

Authors
GEARRY, R. B., & BARCLAY, M. L.
Venue
Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
2005-07
Volume
20
Issue
8
Pages
1149-1157
ISSN
  • 0815-9319 (ISSN-L)
  • 1440-1746
OpenAlex
W1991619620
Cited by
236
References
1
FWCI
5.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. https://app.cochat.ai/papers/10.1111/j.1440-1746.2005.03832.x
The paper
GEARRY, R. B., & BARCLAY, M. L. (2005). Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/j.1440-1746.2005.03832.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.